Continuous Glucose Monitoring for Diabetes in Hemodialysis Patients
(CONDOR Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This randomized controlled trial will investigate whether use of continuous glucose monitoring (CGM) vs. usual care with self-monitored blood glucose 1) enhances glycemic control, 2) reduces hypoglycemia risk, and 3) improves quality of life, diabetes distress, and fear of hypoglycemia in hemodialysis patients with diabetes mellitus.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
Is continuous glucose monitoring safe for humans?
Research indicates that continuous glucose monitoring (CGM) systems are generally safe for humans, including those undergoing procedures like cardiothoracic surgery. While the accuracy and reliability of CGM in specific conditions like hemodialysis need further study, no significant safety concerns have been reported in the available research.12345
How is continuous glucose monitoring (CGM) unique for diabetes patients on hemodialysis?
Continuous glucose monitoring (CGM) is unique for diabetes patients on hemodialysis because it provides real-time tracking of blood sugar levels, helping to manage the frequent blood sugar fluctuations that occur in these patients. Unlike traditional methods, CGM offers continuous data, which can improve glucose control and reduce episodes of low or high blood sugar.13678
What data supports the effectiveness of continuous glucose monitoring (CGM) for diabetes in hemodialysis patients?
Are You a Good Fit for This Trial?
This trial is for adults over 18 with end-stage kidney disease on hemodialysis and diabetes, who have been checking their blood sugar themselves for at least 4 weeks. They must be willing to wear a continuous glucose monitoring device and have done so with good compliance in the pre-trial period.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo continuous glucose monitoring using Dexcom devices or self-monitored blood glucose for 12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Continuous glucose monitoring (CGM)
- Usual care (Self-monitored blood glucose)
Continuous glucose monitoring (CGM) is already approved in United States, European Union for the following indications:
- Diabetes management for patients aged 2 years and older
- Type 1 diabetes
- Type 2 diabetes
- Diabetes management
- Type 1 diabetes
- Type 2 diabetes
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Irvine
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator